Next Article in Journal
Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs: An Update
Next Article in Special Issue
A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept
Previous Article in Journal
Mitochondrial Drugs for Alzheimer Disease
Previous Article in Special Issue
The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension
Pharmaceuticals 2010, 3(1), 1-9; doi:10.3390/ph3010001
Article

Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?

1,2, 1,2, 1,2, 3 and 1,2,*
Received: 2 December 2009; in revised form: 29 December 2009 / Accepted: 31 December 2009 / Published: 5 January 2010
(This article belongs to the Special Issue Antihypertensive Drugs)
View Full-Text   |   Download PDF [86 KB, uploaded 6 January 2010]   |   Browse Figures
Abstract: We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with idiopathic membranous nephropathy (IMN) and > 3 gm proteinuria/day despite angiotensin converting enzyme (ACE) inhibitor therapy titrated to a systolic/diastolic blood pressure < 120/80 mmHg. Blood pressure, 24-hour urinary protein excretion, and creatinine clearance were measured prior to, after two months of combined therapy, and after a 2-month withdrawal period of spironolactone. While systolic and diastolic blood pressure decreased significantly after spironolactone therapy, proteinuria did not improve. Serum potassium increased significantly as well, with three patients requiring resin-binding therapy. Thus, spironolactone seems to have no additional antiproteinuric effects over ACE inhibitor therapy in patients with IMN and nephrotic syndrome and carries the risk of significant hyperkalemia.
Keywords: idiopathic membranous nephropathy; spironolactone; proteinuria; hyperkalemia idiopathic membranous nephropathy; spironolactone; proteinuria; hyperkalemia
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Cravedi, P.; Brusegan, V.; Ruggenenti, P.; Campbell, R.; Remuzzi, G. Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work? Pharmaceuticals 2010, 3, 1-9.

AMA Style

Cravedi P, Brusegan V, Ruggenenti P, Campbell R, Remuzzi G. Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work? Pharmaceuticals. 2010; 3(1):1-9.

Chicago/Turabian Style

Cravedi, Paolo; Brusegan, Varusca; Ruggenenti, Piero; Campbell, Ruth; Remuzzi, Giuseppe. 2010. "Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?" Pharmaceuticals 3, no. 1: 1-9.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert